ArticleNature biomedical engineering2026

Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy.

Xin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.